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Background
Tumors are characterized by uncontrolled proliferation 
of abnormal cells that frequently display morphological 
and functional heterogeneity [1]. Two models have been 
proposed to explain the heterogeneity of tumors, namely 
the  stochastic  [2]  and  hierarchical  models  [3].  The 
stochastic model suggests that all cells within a tumor are 
biologically  homogenous  and,  therefore,  have  equal 
capacity to regenerate the tumor. The hierarchical model, 
also known as the cancer stem cell model, proposes that 
only a small subset of tumor cells, designated cancer stem 
cells  (CSCs)  or  tumor-initiating  cells,  within  a  tumor 
exhibit the capacity to initiate and sustain tumor growth. 
CSCs possess two important properties similar to those 
of  normal  stem  cells,  namely  self-renewal  and 
differentiation  capacity  [4].  Although  CSCs  were  first 
identified 26 years ago in acute myelogenous leukemia 
with the cell surface marker CD34+CD38- [5], the isola-
tion of these cells from solid tumors was accomplished 
only  in  2003  [6].  This  study  showed  that  CD44+CD24- 
cells from breast cancer specimens are able to generate 
xenografts that phenotypically resemble the initial tumor. 
Furthermore, the xenografts could be serially passed to 
generate  similar  tumors,  indicating  the  self-renewal 
ability of these cells. Following this seminal study, CSCs 
were isolated from various solid tumors such as brain, 
colon, pancreas, lung and liver. The isolation of CSCs was 
based on a series of cell surface markers, including CD133 
[7,8],  CD44  [6,9],  CD90  [10],  CD24  [11]  and  EpCAM 
[12,13], as well as functional markers such as ALDH1 [14] 
and ABCB5 [15], and side population (SP) cells [16].
Hepatocellular  carcinoma  (HCC)  is  a  deadly  disease 
with no promising therapeutic options. It is the fifth most 
prevalent cancer in the world, and the third leading cause 
of  cancer-related  death,  with  an  annual  death  rate 
exceeding  500,000.  The  incidence  of  HCC  among  the 
population between the ages of 45 and 60 years is rising 
dramatically, particularly in the western world, due to an 
increase in hepatitis C virus infection, and alcoholic and 
non-alcoholic fatty liver disease. While surgical resection/
ablation and liver transplantation are poten  tially curative, 
the  high  mortality  is  due  to  diagnosis  at  an  advanced 
stage [17,18]. Although the multikinase inhibitor sorafenib 
has recently been approved for treatment of HCC, poor 
response of the late-stage cancer to this and almost all 
other available chemotherapeutic agents continues to be 
a major obstacle to successful HCC therapy. The 5-year 
survival rate for this cancer is only 5%, and the death rate 
is expected to rise in the next 20 years. Primary HCC, the 
most common malignant tumor, accounts for >90% of all 
primary  liver  cancer.  Its  development  is  a  complex, 
multistep process. Elucidation of the molecular mecha-
nisms of liver carcinogenesis is critical to determine the 
specific pathways involved in the initiation and progres-
sion of HCC that will eventually lead to identification of 
novel molecular targets for therapy. As observed in other 
solid tumors, recent studies suggested that CSCs may be 
involved in the development of liver cancer [10,13,19-21]. 
This  review  will  summarize  recent  progress  in  the 
potential role of CSCs in hepatocarcinogenesis.
Abstract
There has been considerable interest in cancer stem 
cells (CSCs) among cancer biologists and clinicians, 
most likely because of their role in the heterogeneity 
of cancer and their potential application in cancer 
therapeutics. Recent studies suggest that CSCs play a 
key role in liver carcinogenesis. A small subpopulation 
of cancer cells with CSC properties has been identified 
and characterized from hepatocellular carcinoma (HCC) 
cell lines, animal models and human primary HCCs. 
Considering the high mortality and ineffectiveness 
of current therapies for HCC, understanding the 
characteristics and function of CSCs is likely to 
lead to development of new therapies resulting 
in improvement of patient survival. This review 
summarizes recent progress in liver cancer stem cell 
research with regard to the identification, cell origin, 
regulation of self-renewal capacity, and therapeutic 
implications of liver CSCs.
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In an early attempt to isolate liver-cancer-specific CSCs, 
SP cells with CSC characteristics were separated from a 
total population of HCC cells [19]. SP sorting was initially 
used  to  detect  hematopoietic  stem  cells  exploiting  the 
ability of these cells to efflux Hoechst 33342 through an 
ATP-binding  cassette  membrane  transporter.  This 
property  contributes  to  multidrug  resistance  of  these 
cells, and this is a key feature of CSCs. Only a very small 
proportion  of  HCC  cells  (0.25%  in  Huh7  and  0.8%  in 
PLC/RPL5  cells)  possess  a  SP  phenotype;  these  show 
higher proliferative and tumorigenic potential compared 
with non-SP cells. Indeed, 1 × 103 SP cells were sufficient 
for tumor formation in xenograft transplantation while at 
least 1 × 106 unsorted HCC cells were required to form a 
tumor, indicating enrichment of CSCs in SP cells. Despite 
these key observations, it remains uncertain whether SP 
cells are authentic CSCs, since Hoechst 33342 is cyto-
toxic, and non-SP cells are unable to grow in the presence 
of  this  dye.  Consequently,  differential  resistance  to 
Hoechst 33342 rather than the intrinsic difference in the 
stem cell properties between SP and non-SP cells could 
contribute to the difference in tumor formation between 
these cell types.
In  the  ensuing  several  years,  significant  efforts  were 
made to identify CSCs in HCC cell lines, mouse models 
and  primary  HCC  (Table  1).  CD133,  also  known  as 
prominin-1 (Prom1), encoding a pentaspan transmem-
brane glycoprotein [22,23], has been used as a marker for 
both  somatic  stem  cells  [24-26]  and  CSCs  in  different 
tissues, including brain [7], colon [8], pancreas [27] and 
skin  [28].  Recently,  several  studies  have  shown  that 
CD133+ cells isolated from various liver cancer cell lines 
[20,21,29] exhibit the properties of CSCs and only a small 
fraction  of  CD133+  cells  produce  hepatocellular  carci-
noma  in  severe  combined  immunodeficiency  mice. 
Although CD133 has been used to identify CSCs from 
HCC  cell  lines  and  mouse  models,  some  studies  have 
suggested that CD133- cells can form tumors in immuno-
deficient mice at higher cell number [21], indicating that 
CD133 may not be an effective CSC marker in HCC. To 
identify CSCs in human primary HCC specimens, Yang 
et al. [10] used CD90 cell surface markers and found that, 
unlike CD90- cells, CD90+ cells from HCC specimens as 
well  as  patient  blood  samples  exhibited  tumorigenic 
potential.  This  study  suggested  that  CD90  is  a  potent 
marker of liver CSCs and that circu  lating CSCs probably 
contributed to tumor metastasis.
Since CSCs share key features with normal stem cells, 
including self-renewal and differentiation, it is con  ceivable 
that these cells may possess similar cell surface markers. 
Indeed, some markers, such as EpCAM [13] and OV6 [30], 
that were used to isolate hepatic stem cells have also been 
shown to function as specific markers for CSCs in HCC.
Cellular origin of liver CSCs
It  has  been  proposed  that  CSCs  may  arise  through 
mutations accrued in normal tissue stem cells or more 
differentiated tissue progenitor cells [31]. Recently, crypt 
cells expressing Lgr5 in small intestine and colon tissues 
have  been  identified  as  long-lived  stem  cells  [32].  Apc 
deletion  in  these  cells  was  necessary  and  sufficient  to 
produce tumors in vivo [32]. Another study showed that 
CD133  marks  the  intestinal  stem  cells,  and  over-
production of β-catenin can transform CD133+ cells into 
CSCs and generate tumors [33]. Those studies suggested 
that  normal  stem  cells  may  be  the  origin  of  CSCs.  In 
contrast,  introduction  of  MLL-AF9  into  committed 
granulo  cyte macrophage progenitors produced leukemia 
stem  cells  [34],  suggesting  that  CSCs  could  also  be 
derived from committed progenitors.
The  existence  of  stem  cells  in  adult  liver  has  been 
debated for many years. Recent studies have suggested 
that hepatic progenitor cells (HPCs) or oval cells, a subset 
of small epithelial cells with an oval nucleus located in 
the bile ductules and canals of Hering in adult liver [35], 
may function as stem cells in adult liver. HPCs can be 
activated to proliferate and differentiate into hepatocytes 
and  biliary  lineage  in  response  to  severe  liver  damage 
[36-41], such as that induced by treatment of rats with 
2-acetylaminofluorene  after  partial  hepatectomy  (AAF/
PH model) [42]. Under this condition, hepatocytes were 
unable to proliferate to replace the lost tissues. HPCs are, 
therefore, considered to be the bipotent liver stem cells.
HPCs  play  an  important  role  in  carcinogenesis  in  at 
least some subtypes of HCC. The number of HPCs in 
human chronic liver diseases, such as hepatitis B and C 
infection and alcoholic liver disease, are directly related 
to disease severity, suggesting that oval cell proliferation 
is associated with increased risk of development of HCC 
Table 1. Cell surface markers of liver cancer stem cells
Marker  Cell line/primary tumor  Reference
Side   Huh7 and PLC/PRF/5 cell lines  Chiba et al. 
population    (2006) [19]
CD133+  SMMC-7721 cell line, human primary   Yin et al. (2007) 
  HCC  [20]
CD133+  Huh7, PLC8024, Hep3B cell lines, human   Ma et al. (2007) 
  primary HCC   [21]
CD133+ CD44+  SMMC-7721, MHCC-LM3 and MHCC-97L   Zhu et al. (2010) 
  cell lines  [29]
CD90  HepG2, Hep3B, PLC, Huh7, MHCC97L,   Yang et al. 
  and MHCC97H cell lines, human primary   (2008) [10] 
  HCC 
EpCAM  HuH1, HuH7, and Hep3B cell lines,   Yamashita et al. 
  human primary HCC   (2009) [13]
OV6  Huh7, PLC, SMMC7721, Hep3B, and   Yang et al. 
  HepG2 cell lines  (2008) [30]
HCC, hepatocellular carcinoma.
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that certain subtypes of primary human HCCs with poor 
prognosis may be derived from HPCs [43], based on the 
identification  of  human  HCCs  that  exhibited  gene 
expression  profiles  identical  to  that  of  hepatoblasts. 
Further, this subtype of HCC can be distinguished from 
other  types  by  the  markers  of  HPCs.  HPCs  are  also 
activated  in  several  mouse  models  of  hepatocarcino-
genesis, suggesting their potential role in the initiation 
and progression of liver cancer [44-48]. Fang et al. [44] 
found that oval cell proliferation was prominent from the 
initial liver injury stage to the occurrence and develop-
ment of HCC in a HCC model fed 3,3’-diamino  benzidine. 
More importantly, blocking the expansion of oval cells by 
targeting  c-Kit  with  imatinib  mesylate  significantly 
reduced  liver  tumor  formation  in  mice  fed  a  choline-
deficient,  ethionine-supplemented  diet  [49].  Similarly, 
TNF  was  upregulated  during  oval  cell  prolifera  tion 
induced by a choline-deficient, ethionine-supplemented 
diet,  and  was  produced  by  oval  cells  [50].  Oval  cell 
proliferation  and  tumorigenesis  were  substantially  im-
paired in TNF receptor type 1 knockout mice. These two 
studies suggested that oval cells may be directly involved 
in the initiation and progression of liver cancer in this 
mouse model. More direct evidence for the involvement 
of oval cells in hepatocarcinogenesis was revealed in a 
study that demonstrated tumor formation in nude mice 
upon subcutaneous injection of p53 null oval cells [46]. 
Further  studies  showed  that  CD133+CD45-  oval  cells 
isolated from Mat1a (methionine adenosyltransferase 1a) 
[51] and Pten (phosphatase and tensin homolog deleted 
on chromosome 10) [52] knockout mice exhibited greater 
tumorigenic  capacity.  Furthermore,  these  oval  cells 
exhibited high levels of resistance to chemotherapeutic 
agents, consistent with cancer stem cell characteristics. 
These findings, together with the notion that CSCs may 
arise from adult stem cells or progenitor cells, suggest 
that liver CSCs are probably derived from HPCs.
However, it should be noted that not all HCCs arise 
from HPCs, since oval cell proliferation is very rare in 
diethylnitrosamine-induced  HCC.  It  is  widely  accepted 
that the HCC induced by this carcinogen develops from 
hepatocytes [53]. Based on these observations, the exact 
origin  of  CSCs  in  the  liver  appears  to  depend  on  the 
etiology of the cancer.
Signaling pathways involved in maintaining the 
characteristics of liver CSCs
The maintenance of self-renewal and tumorigenic capacity 
of CSCs involves several cancer-related signaling path-
ways, including Bmi-1 [54], Wnt/β-catenin [55], Notch 
[56],  and  Sonic  Hedgehog  [55,57]  (Figure  1).  Bmi-1,  a 
polycomb group (PcG) gene, has previously been shown 
to regulate the self-renewal of hematopoietic stem cells 
[58]. Overexpression of Bmi-1 enhanced self-renewal of 
both  hematopoietic  stem  cells  and  neural  stem  cells, 
indicating that Bmi-1 may function as a universal deter-
minant  of  stem  cell  self-renewal.  Overexpression  of 
Bmi-1 in HPCs dramatically promoted the self-renewal 
of these cells, and transplantation of Bmi-1-transduced 
HPCs produced tumors in vivo, indicating the important 
role of Bmi-1 in regulating the self-renewal of normal or 
cancer stem cells in the liver [54]. Notably, upregulation 
of  Bmi-1  has  also  frequently  been  observed  in  human 
primary HCC [59].
The Wnt/β-catenin signaling pathway can play a critical 
role in stem cell proliferation and potency maintenance 
[60], as well as differentiation of stem cells in a variety of 
tissues  [61].  The  activation  of  Wnt/β-catenin  has  been 
shown to be associated with hepatocyte proliferation in 
liver development, regeneration and tumor growth [62]. 
As  observed  in  Bmi-1,  mutation  in  β-catenin  and 
Figure 1. Proposed model for the cell origin and transformation of liver cancer stem cells. Dysregulation of signaling pathways involved in 
self-renewal and proliferation of normal stem cells (hepatic progenitor cells, HPCs) is likely to cause uncontrolled proliferation and increased self-
renewal capacity of HPCs, resulting in the transformation of HPCs into cancer stem cells (CSCs). HCC, hepatocellular carcinoma.
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cantly enhanced the self-renewal of HPCs and promoted 
cancer initiation [54].
Although  the  Notch  signaling  pathway  plays  an 
important role in regulating stem cell self-renewal and 
differentiation [3], it may function as a tumor suppressor 
or  oncogene  in  different  tissues  depending  on  other 
signaling  pathways  [63].  In  breast  tissue,  the  Notch 
signaling  pathway  was  shown  to  be  upregulated,  and 
inhibition of the Notch pathway reduced the formation 
of  mammosphere,  an  indicator  of  stem-like  cells  [56]. 
Similarly,  inhibition  of  the  Notch  pathway  selectively 
depleted glioblastoma CSCs [64]. The role of the Notch 
signaling  pathway  in  HCC  is  controversial.  One  study 
found that activation of Notch1 signaling inhibits growth 
of human HCC [65], suggesting that it may function as a 
tumor suppressor. In contrast, another study showed that 
the Notch1 signaling pathway is constitutively activated 
in HCC [66], indicating a potential oncogenic role of this 
pathway in HCC.
A variety of tumors exhibit activating mutations or up-
regulation  of  Sonic  Hedgehog  (HH)  pathway  compo-
nents,  such  as  PTCH1,  SMO  and  GLI1[67].  Recent 
studies showed that the HH pathway also regulates the 
self-renewal ability of CSCs in breast cancer [68], glioma 
[69] and multiple myeloma [70]. Although the role of the 
HH  pathway  in  liver  CSCs  has  not  been  well  charac-
terized, this pathway is known to be activated in HCC 
[71]. It would be of interest to investigate its potential 
role in regulating the self-renewal ability of liver CSCs.
Therapeutic implications of liver CSCs
Recent studies have shown that CSCs are more resistant 
to chemotherapy [11,72] and radiotherapy [73] compared 
with non-CSCs within the same tumor, indicating that 
CSCs may be responsible for the recurrence and eventual 
metastasis of these tumors. It is conceivable that targeting 
liver CSCs would provide new alternatives to treat HCC, 
since  HCC  is  more  resistant  to  traditional  therapies. 
Drugs targeting signaling pathways involved in regulating 
the self-renewal ability of CSCs may prove to be effective 
in HCC therapy. For example, cyclopamine, which targets 
the HH pathway, significantly reduces the self-renewal of 
glioma [74], whereas gamma secretase inhibitor, which 
targets  the  Notch  pathway,  decreases  self-renewal  of 
breast CSCs [75]. It is worth investigating whether such 
drugs can also effectively eliminate liver CSCs. Another 
strategy to target CSCs is to induce differentiation of liver 
CSCs. In this context, Yin et al. [76] have shown that the 
forced expression of HNF4α, a central regulator of the 
differentiated hepatocyte phenotype, in CSCs can induce 
the differentiation of CSCs into mature hepatocytes and 
abolish their tumorigenesis in mice, implicating a novel 
strategy for HCC therapy.
Conclusions
Although  significant  progress  has  been  made  in  liver 
cancer stem cell research in HCC, many issues remain to 
be resolved, such as the identity and origin of liver CSCs. 
Several  markers  are  currently  used  to  isolate  CSCs. 
Although CSCs thus identified are known to form tumors 
in  a  xenograft  model,  it  is  not  known  whether  these 
markers coexist or whether they are present in different 
cells. Additionally, the origin of liver CSCs needs to be 
studied by a lineage tracing study. The development of 
single cell sorting and in vivo imaging technology, as well 
as the use of mouse HCC models and syngeneic trans-
plantation, will facilitate the identification of unique and 
specific liver CSC markers. It is critical to elucidate the 
detailed  mechanisms  underlying  the  transformation  of 
liver  CSCs.  Comparing  the  gene  expression  profiles 
between normal stem cells (HPCs) and CSCs by micro-
array analysis or next-generation sequencing may prove 
to  be  useful  to  identify  the  dysregulated  oncogenes  or 
tumor  suppressors  and  signaling  pathways  that  are 
involved  in  the  transformation  of  liver  CSCs.  Finally, 
these findings are likely to lead to the development of 
new diagnostic markers and therapeutic targets for HCC.
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